Walvax Biotechnology (300142.SZ) subsidiary received 13-valent pneumococcal conjugate vaccine Egypt market license.

Walvax Biotechnology (300142.SZ) announced that its subsidiary, Yuxi Walvax Biotechnology Technology Co., Ltd. (referred to as "Yuxi Walvax"), has recently received a Biologics Marketing Authorization from the Egyptian Drug Authority (EDA) for the production of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (referred to as "13-valent Pneumococcal Conjugate Vaccine"). This marks the approval of the vaccine for marketing in Egypt.